Pembrolizumab
KEYNOTE-679/ECHO-302
Phase 3 small_molecule completed
Quick answer
Pembrolizumab for Renal Cell Carcinoma (RCC) is a Phase 3 program (small_molecule) at Incyte with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Incyte
- Indication
- Renal Cell Carcinoma (RCC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed